Experts warn about antioxidant supplements

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 6
Volume 17
Issue 6

Cancer patients should avoid the routine use of antioxidant supplements, such as vitamin A or beta-carotene, during radiation and chemotherapy because the supplements may reduce the anticancer benefits of therapy, Brian D. Lawenda, MD, of the Naval Medical Center San Diego, and colleagues concluded (J Natl Cancer Inst 100:773-783, 2008).

Cancer patients should avoid the routine use of antioxidant supplements, such as vitamin A or beta-carotene, during radiation and chemotherapy because the supplements may reduce the anticancer benefits of therapy, Brian D. Lawenda, MD, of the Naval Medical Center San Diego, and colleagues concluded (J Natl Cancer Inst 100:773-783, 2008). The authors reviewed 9 radiotherapy studies and 16 chemotherapy studies that addressed the issue.

“Despite some intriguing studies that have suggested the benefit of adjunctive antioxidant treatment in cancer patients, the totality of the available evidence is equivocal at best and leaves us with serious concerns about the potential for harm,” the authors wrote.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content